A

Amgen

Makes biotech medicines for serious illnesses

Senior Associate Supply Chain – RMD Buyer Lead

Full-TimeUpdated on 10/21/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • Bachelor’s Degree or Master's Degree and 5–9 years of experience in Supply Chain, Procurement, Purchasing, Operations, or a related field.
  • Experience in procurement, purchasing, supply chain execution, or operations.
  • Strong SAP experience, including Purchasing, Material Master, and Vendor Master processes.
  • Experience with Ariba Network (AIN) invoice processing and supplier collaboration.
  • Knowledge of Purchasing Info Records (PIRs), lead times, sourcing, and procurement master data.
  • Experience managing purchase orders and supplier order execution.
  • Experience in a regulated manufacturing, pharmaceutical, biotechnology, or healthcare environment is preferred.
  • Knowledge of continuous improvement methodologies and operational excellence principles.
Responsibilities
  • Execute procurement activities based on planning signals and system-generated requirements.
  • Monitor and respond to supply exceptions to ensure continuity of material supply.
  • Collaborate with Network Planners to understand demand changes and execute required procurement actions.
  • Escalate supply risks, delays, and exceptions to appropriate stakeholders.
  • Create, release, and manage purchase orders in SAP.
  • Communicate purchase orders and schedule requirements to suppliers.
  • Maintain purchase order accuracy, including quantities, delivery dates, pricing, and confirmations.
  • Monitor open orders and proactively resolve discrepancies impacting supply.
  • Process purchase order updates, cancellations, and rescheduling requests.
  • Manage supplier confirmations and delivery commitments.
  • Coordinate with suppliers to resolve order execution issues and delivery exceptions.
  • Support supplier performance through timely communication and issue resolution.
  • Review, process, and resolve invoice discrepancies through Ariba Network (AIN) and SAP.
  • Partner with Accounts Payable, suppliers, and procurement teams to resolve blocked invoices and payment issues.
  • Ensure invoice processing compliance with company policies and procedures.
  • Monitor invoice workflow status and drive timely resolution of exceptions.
  • Maintain accurate procurement and material master data within SAP.
  • Update and manage Purchasing Info Records (PIRs), lead times, sourcing information, and procurement parameters.
  • Ensure transactional accuracy across procurement systems.
  • Support system audits and data quality initiatives.
  • Support creation and maintenance of supplier, material, and purchasing master data.
  • Monitor workflow queues and resolve pending approvals.
  • Ensure compliance with established business processes and data governance standards.
  • Partner closely with Network Planners to execute procurement requirements and manage supply exceptions.
  • Collaborate with Manufacturing, Warehouse, Quality, Procurement, and Finance teams.
  • Provide timely updates regarding order status, supplier commitments, and execution risks.
  • Participate in operational reviews and continuous improvement initiatives.
  • Execute procurement activities in accordance with planning signals and established business processes.
  • Ensure purchase orders are created, maintained, and closed accurately.
  • Maintain high levels of SAP master data integrity and transactional accuracy.
  • Resolve invoice exceptions and workflow issues within established service levels.
  • Support supplier performance through proactive order management and communication.
  • Maintain compliance with procurement policies, quality requirements, and regulatory expectations.
  • Identify opportunities to improve efficiency, automation, and process performance.
Desired Qualifications
  • Strong analytical and problem-solving skills.
  • High attention to detail and commitment to data accuracy.
  • Effective communication and stakeholder management skills.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.